Micro-X Secures $1.6M from ARPA-H After Full Body CT Test Bench Success
Micro-X has reached a key development milestone with the completion of its first Full Body CT laboratory test bench, securing a $1.6 million payment from US government partner ARPA-H and advancing its innovative medical imaging program.
- Completion of first Full Body CT laboratory test bench
- Secured $1.6 million milestone payment from ARPA-H
- Advancement to critical design review phase
- Significant derisking of the ARPA-H Full Body CT program
- Ongoing development and validation work ahead
Micro-X Advances Full Body CT Development
Australian medical imaging innovator Micro-X Ltd (ASX:MX1) has marked a significant step forward in its Full Body CT program by completing the first laboratory test bench. This milestone achievement triggers a $1.6 million payment from the US government’s Advanced Research Projects Agency for Health (ARPA-H), underscoring the progress of this cutting-edge project.
The Full Body CT test bench represents a crucial engineering accomplishment, moving Micro-X beyond early prototyping into a phase focused on physical system development. The company recently passed a preliminary design review, confirming the system architecture and setting the stage for a critical design review phase.
Significance of the Milestone
This milestone payment and test bench completion are more than just financial markers; they signify meaningful derisking of the program. By demonstrating a working laboratory model, Micro-X has validated key aspects of its proprietary cold cathode X-ray technology, which promises to revolutionise full body CT imaging with reduced size, weight, and power consumption.
Despite this progress, the company acknowledges that substantial development, validation, and integration work remains. The program is still in its first phase, with ongoing efforts to refine the system architecture and prepare the platform for future clinical readiness.
Strategic Positioning and Future Outlook
Micro-X’s vertically integrated operations in Adelaide, combined with its expanding US presence, position it well to capitalise on this technology’s potential. The Full Body CT system could open new frontiers in medical imaging, offering more mobile and efficient diagnostic tools for healthcare providers globally.
As the project advances into the critical design review phase, investors and industry watchers will be keenly observing how Micro-X navigates the technical challenges ahead and moves towards clinical validation and commercialisation.
Bottom Line?
Micro-X’s milestone signals strong momentum but the path to clinical and commercial success remains complex and demanding.
Questions in the middle?
- How will Micro-X manage the technical risks in the next development phases?
- What is the timeline for clinical trials and regulatory approvals?
- How might this technology disrupt existing full body CT markets?
